Document text
Principal Investigator: THOMAS M WISNIEWSKI
Organization: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Fiscal Year: 2024
Award: $39,934
Funding agency: National Institute on Aging
Since its inception in 1990, the Alzheimer's Disease Research Center (ADRC) at New York University Langone
Health has facilitated pioneering research to define transitions from normal aging to the subjective cognitive
decline (SCD), mild cognitive impairment (MCI), and early dementia stages of AD; as well as AD biomarker
development. Here we propose to continue this long-standing successful research direction with a focus on
understanding disease heterogeneity and delineating biomarkers and their role in these transitions, with
the long-term goal of helping to develop novel interventions that will delay or prevent cognitive decline.
The NYU ADRC has built an infrastructure that supports innovative research on AD and related dementias
(ADRD) to help achieve the NAPA goal of a cure by 2025. This will be facilitated by our nine highly successful
and interactive Cores (Admin; Clinical; Data Management & Statistical [DMS]; Neuropathology; Outreach,
Education & Engagement [ORE]; Neuroimaging; Biomarker; Psychosocial; and Research Education Component
[REC]). Together, our highly integrated cores will achieve the following aims: Aim 1. Enhance the performance
of innovative research in ADRC by maintaining nine cores that focus on delineating biomarkers of the transitions
from normal aging to SCD, MCI, and early dementia, and determining their roles to help develop novel
interventions that delay or prevent these transitions. We will also facilitate training in this area. Aim 2. Contribute
to the national network of ADRCs by providing clinical data, autopsy diagnoses, neuroimaging and biosamples
to NACC and NCRAD, as well as to other research community collaborative efforts in ADRD. Aim 3. Recruit and
retain a diverse subject population from clinical and community settings, via the ORE and Psychosocial Cores,
with concomitant engagement of the local scientific and lay community in ADRD with seminars, poster sessions
and the developmental projects via the Admin, ORE, and REC Cores. Aim 4. Foster the development of novel
avenues of investigation with methodological developments by the cores (via innovative cognitive assessments,
neuroimaging techniques, biomarkers and proteomic approaches), and encourage, recruit, and select
developmental projects. Aim 5. Accelerate translational research across the ADRD spectrum by using
biomarkers to better define the underlying disease heterogeneity and foster the development of novel therapeutic
interventions that consider this heterogeneity. Aim 6. Facilitate the education and training of a diverse ADRD
workforce. Our Center will enhance the scientific community's understanding of ADRD and expand the next
generation of diverse ADRD scientists, via combined efforts of the Admin, ORE, and REC Cores. In summary,
the NYU ADRD has facilitated pioneering research that defined the stage transitions from normal aging to
dementia, and contributed to AD biomarker development from its inception. In the next five years of funding, this
focus will be expanded by: 1) improving our understanding of disease heterogeneity; 2) identifying new biomarkers
that will allow early detection; and 3) fostering research that will develop effective therapeutic interventions.
Terms: <AD dementia><Acceleration><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimers Dementia><Amentia><Amyloid><Amyloid Substance><Area><Assay><Autopsy><Behavioral><Bioassay><Biological Assay><Biological Markers><Blood Plasma><Blood Serum><Cerebrospinal Fluid><Clinical><Clinical Data><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Collaborations><Communities><Counseling><Cyclotrons><Data Linkages><Data Set><Dementia><Development><Diagnosis><Diagnostic Services><Disturbance in cognition><Early Diagnosis><Education><Education and Training><Educational aspects><Epidemiologic Research><Epidemiologic Studies><Epidemiological Studies><Epidemiology Research><Fostering><Funding><Goals><Health><Heterogeneity><Impaired cognition><Infrastructure><Intervention><Intervention Strategies><Investigation><Laboratories><MR Imaging><MR Tomography><MRI><MRIs><MT-bound tau><Magnetic Resonance Imaging><Measures><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Mental Depression><Methodology><Mission><NMR Imaging><NMR Tomography><Neuropsychologies><Neuropsychology><New York><Nuclear Magnetic Resonance Imaging><PET><PET Scan><PET imaging><PETSCAN><PETT><Participant><Pathology><Patients><Performance><Phenotype><Plasma><Plasma Serum><Population><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Primary Senile Degenerative Dementia><Proteomics><Psychological Impact><Rad.-PET><Radiation Chemistry><Radiochemistry><Record Linkage Study><Research><Reticuloendothelial System, Serum, Plasma><Role><Scanning><Scientist><Secure><Serum><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Stress><Techniques><Therapeutic Intervention><Time><Training><Training and Education><Translational Research><Translational Science><Universities><Update><Work><Zeugmatography><aged><aged brain><aging brain><bio-markers><biologic marker><biomarker><biomarker development><biomarker identification><cerebral spinal fluid><clinical training><cognitive assessment><cognitive dysfunction><cognitive function><cognitive loss><cognitive testing><community setting><data management><depression><developmental><diagnosis service><disease heterogeneity><early detection><education research><epidemiologic investigation><epidemiology study><iPS><iPSC><iPSCs><identification of biomarkers><identification of new biomarkers><improved><in vivo><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent stem cell><innovate><innovation><innovative><intervention therapy><interventional strategy><marker identification><microtubule bound tau><microtubule-bound tau><mild cognitive disorder><mild cognitive impairment><natural aging><necropsy><neural imaging><neuro-imaging><neuroimaging><neurological imaging><neuropathologic><neuropathological><neuropathology><neuropsychologic><new marker><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><next generation><normal aging><normative aging><novel><novel biomarker><novel marker><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><outreach><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><posters><postmortem><prevent><preventing><primary degenerative dementia><programs><psychosocial><recruit><senile dementia of the Alzheimer type><social factors><social role><socio-demographic variables><sociodemographic variables><spinal fluid><statistical analysis><tau><tau Proteins><tau factor><therapeutically effective><translation research><translational investigation><τ Proteins>